BOSTON, Sept. 4, 2013 /PRNewswire/ -- BlazeFund, a new equity crowd funding company in Boston, Massachusetts, has listed the first biotech company on their platform. Atlanta-based Perle BioScience is a life sciences company whose mission is to address patient needs that have been considered "impossible" to tackle.
Perle BioScience's founder, Dr. Claresa Levetan, is internationally recognized as a leader of diabetes research. She previously co-founded CureDM and was a lead inventor of a therapeutic drug for the reversal of diabetes. CureDM's IP portfolio was licensed to Sanofi in 2010 for upfront and commercial milestone payments of a potential value totaling $335M.
Dr. Levetan is raising capital for Perle BioScience to "pave the way for a revolutionary therapeutic treatment which will create a transformational shift in the treatment of diabetes," states Dr. Levetan. According to the American Diabetes Association, there are currently 26 million diabetes patients in the US.
Dr. Levetan indicates, "Nearly 1 out of 10 healthcare dollars or 4 out of 10 Medicare dollars are spent on patients with diabetes. As health care costs are spiraling and the diabetes population is growing, Perle BioScience is looking to address the underlying mechanisms that cause diabetes. Our treatment will be a huge benefit to society as a whole – not just for diabetic patients - but also in terms of managing healthcare costs."
Perle BioScience elected to utilize equity crowd funding to obtain the company's growth capital. Dr. Levetan mentions, "Perle is making a paradigm shift in the treatment of diabetes, and we specifically chose equity crowd funding, which is a perfect fit, since it is creating a paradigm shift as it relates to accessing capital. The ability to expose our company's technology to so many types of investors, from small to large, is invaluable. More importantly, we specifically selected BlazeFund based on their healthcare/ life science focus and the experience of their leadership team."
Aaron Sanders, CEO of BlazeFund, adds, "BlazeFund provides the entire investment community with exposure and access to innovative ventures. We are very proud and enthusiastic to be working with an industry leader that has the caliber of Perle BioScience."
For more information about BlazeFund please contact:
Aaron Sanders, CEO & Founder
Copyright©2012 PR Newswire.
All rights reserved